DOP2011000016A - Composiciones y metodos de uso para anticuerpos terapeuticos - Google Patents

Composiciones y metodos de uso para anticuerpos terapeuticos

Info

Publication number
DOP2011000016A
DOP2011000016A DO2011000016A DO2011000016A DOP2011000016A DO P2011000016 A DOP2011000016 A DO P2011000016A DO 2011000016 A DO2011000016 A DO 2011000016A DO 2011000016 A DO2011000016 A DO 2011000016A DO P2011000016 A DOP2011000016 A DO P2011000016A
Authority
DO
Dominican Republic
Prior art keywords
antibodies
compositions
methods
therapeutic antibodies
baffr
Prior art date
Application number
DO2011000016A
Other languages
English (en)
Inventor
Christoph Heusser
Julia Neugebauer
Eveline Schaadt
Stefanie Urlinger
Maximilian Woisetschlaeger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41073830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2011000016(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of DOP2011000016A publication Critical patent/DOP2011000016A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74Inducing cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Anticuerpos que se enlazan específicamente al receptor de BAFF (BAFFR). De una manera más específica, anticuerpos que son antagonistas del BAFFR, con actividad consumidora de células-B ¡n vivo, y composiciones y métodos de uso para estos anticuerpos con el fin de tratar los trastornos patológicos que puedan ser tratados mediante la aniquilación o el consumo de las cétulas-B, tales como lupus eritematoso sistémico o artritis reumatoide, u otras enfermedades autoinmunes o linfomas, leucemias, y mielomas.
DO2011000016A 2008-07-17 2011-01-14 Composiciones y metodos de uso para anticuerpos terapeuticos DOP2011000016A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08160671 2008-07-17
EP09160326 2009-05-15

Publications (1)

Publication Number Publication Date
DOP2011000016A true DOP2011000016A (es) 2011-02-15

Family

ID=41073830

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2011000016A DOP2011000016A (es) 2008-07-17 2011-01-14 Composiciones y metodos de uso para anticuerpos terapeuticos

Country Status (41)

Country Link
US (3) US8106163B2 (es)
EP (1) EP2315780B8 (es)
JP (2) JP5767109B2 (es)
KR (2) KR101314369B1 (es)
CN (1) CN102119174B (es)
AR (1) AR072749A1 (es)
AU (1) AU2009272771B2 (es)
BR (1) BRPI0915928B8 (es)
CA (1) CA2730063C (es)
CL (1) CL2011000086A1 (es)
CR (1) CR11863A (es)
CU (1) CU23878B1 (es)
CY (1) CY1116800T1 (es)
DK (1) DK2315780T3 (es)
DO (1) DOP2011000016A (es)
EA (1) EA024492B1 (es)
EC (1) ECSP11010761A (es)
ES (1) ES2547270T3 (es)
GE (1) GEP20146129B (es)
HK (1) HK1150839A1 (es)
HR (1) HRP20151227T1 (es)
HU (1) HUE025778T2 (es)
IL (1) IL210485A (es)
JO (1) JO3149B1 (es)
MA (1) MA32481B1 (es)
MX (1) MX2011000616A (es)
MY (1) MY158980A (es)
NI (1) NI201100017A (es)
NZ (1) NZ590057A (es)
PE (1) PE20110563A1 (es)
PL (1) PL2315780T3 (es)
PT (1) PT2315780E (es)
RS (1) RS54299B1 (es)
SG (1) SG193805A1 (es)
SI (1) SI2315780T1 (es)
SM (1) SMP201100010B (es)
SV (1) SV2011003807A (es)
TW (1) TWI508742B (es)
UY (1) UY31987A (es)
WO (1) WO2010007082A1 (es)
ZA (1) ZA201008952B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
AU2008287426B2 (en) * 2007-08-10 2014-06-26 Protelica, Inc. Universal fibronectin type III binding-domain libraries
WO2012076670A2 (en) 2010-12-10 2012-06-14 Novartis Ag Antibody formulation
JP2012153788A (ja) * 2011-01-25 2012-08-16 Nitto Denko Corp 光学用粘着シート
US9216219B2 (en) * 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
WO2015100246A1 (en) 2013-12-24 2015-07-02 Ossianix, Inc. Baff selective binding compounds and related methods
KR20160113715A (ko) 2014-01-31 2016-09-30 베링거 인겔하임 인터내셔날 게엠베하 신규한 항-baff 항체
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
ES2952717T3 (es) 2014-10-14 2023-11-03 Novartis Ag Moléculas de anticuerpos contra PD-L1 y usos de las mismas
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
CN114272371A (zh) 2015-07-29 2022-04-05 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
LT3317301T (lt) 2015-07-29 2021-07-26 Novartis Ag Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
EP3389712B1 (en) 2015-12-17 2024-04-10 Novartis AG Antibody molecules to pd-1 and uses thereof
AU2017204936B2 (en) 2016-02-10 2019-06-27 Novartis Ag Use of inhibitors of the activity or function of PI3K for the treatment of primary Sjogren's Syndrome
WO2017214170A2 (en) * 2016-06-06 2017-12-14 City Of Hope Baff-r antibodies and uses thereof
US11197928B2 (en) 2017-01-13 2021-12-14 Board Of Regents, The University Of Texas System Sustained production of high affinity antigen specific antibody by high dose BAFF receptor-targeting mAb-siRNA conjugate
RU2770209C2 (ru) * 2017-05-24 2022-04-14 ЭйЭлЭс ТЕРАПИ ДЕВЕЛОПМЕНТ ИНСТИТЬЮТ Терапевтические антитела против лиганда cd40
BR112019026907A2 (pt) 2017-06-20 2020-06-30 Teneobio, Inc. Anticorpos apenas de cadeia pesadaanti-bcma, polinucleotídeo, vetor, célula,composição farmacêutica, seus usos e método paraproduzir os mesmos
US20210332133A1 (en) * 2018-07-20 2021-10-28 Teneobio, Inc. Heavy chain antibodies binding to cd19
WO2020202839A1 (ja) * 2019-03-29 2020-10-08 中外製薬株式会社 抗il-6受容体抗体を含有するbbb機能低下の抑制剤
JP2023501781A (ja) 2019-11-06 2023-01-19 ノバルティス アーゲー シェーグレン症候群の処置
CN112813099A (zh) * 2019-11-15 2021-05-18 上海细胞治疗集团有限公司 一种在活化的t细胞中具有高活性的启动子
IL300086A (en) 2020-08-04 2023-03-01 Novartis Ag Treatment of B-cell malignancies
TW202206103A (zh) 2020-08-04 2022-02-16 瑞士商諾華公司 Cll的治療
CN114149504B (zh) * 2020-09-07 2024-01-12 白先宏 Baff-r结合分子及其应用
WO2022097061A1 (en) 2020-11-06 2022-05-12 Novartis Ag Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
CN115073598B (zh) * 2021-03-15 2024-02-20 盛禾(中国)生物制药有限公司 一种抗baffr抗体及其应用
CN117203240A (zh) 2021-05-04 2023-12-08 诺华股份有限公司 使用抗baffr抗体治疗狼疮肾炎
EP4334351A1 (en) 2021-05-04 2024-03-13 Novartis AG Treatment for systemic lupus erythematosus using anti-baffr antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05673B1 (et) * 1999-08-17 2013-08-15 Biogen, Inc. BAFF-retseptor (BCMA), immunoregulatoorne agens
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
EA200701211A1 (ru) * 2004-12-31 2007-12-28 Дженентек, Инк. Полипептиды, которые связываются с br3, и их применение
WO2008008482A2 (en) * 2006-07-13 2008-01-17 Genentech, Inc. Altered br3-binding polypeptides

Also Published As

Publication number Publication date
US8106163B2 (en) 2012-01-31
US20120195913A1 (en) 2012-08-02
CR11863A (es) 2011-02-11
KR101314369B1 (ko) 2013-10-10
WO2010007082A1 (en) 2010-01-21
AU2009272771B2 (en) 2012-09-20
CN102119174B (zh) 2015-01-21
PT2315780E (pt) 2015-11-30
PL2315780T3 (pl) 2016-01-29
CU23878B1 (es) 2013-04-19
JP2011527896A (ja) 2011-11-10
NI201100017A (es) 2012-08-17
DK2315780T3 (en) 2015-10-19
CN102119174A (zh) 2011-07-06
ZA201008952B (en) 2012-01-25
EP2315780A1 (en) 2011-05-04
BRPI0915928A2 (pt) 2015-11-03
RS54299B1 (en) 2016-02-29
MY158980A (en) 2016-11-30
CY1116800T1 (el) 2017-03-15
AR072749A1 (es) 2010-09-15
ES2547270T3 (es) 2015-10-05
IL210485A (en) 2015-03-31
EA024492B1 (ru) 2016-09-30
SV2011003807A (es) 2011-03-23
EP2315780B8 (en) 2015-09-23
SMAP201100010A (it) 2011-05-06
US20120183529A1 (en) 2012-07-19
HUE025778T2 (en) 2016-05-30
JP6077587B2 (ja) 2017-02-08
SG193805A1 (en) 2013-10-30
KR101545795B1 (ko) 2015-08-19
CL2011000086A1 (es) 2011-07-01
HK1150839A1 (en) 2012-01-13
SMP201100010B (it) 2011-09-09
ECSP11010761A (es) 2011-02-28
MA32481B1 (fr) 2011-07-03
PE20110563A1 (es) 2011-08-29
NZ590057A (en) 2012-08-31
CU20110013A7 (es) 2012-06-21
JP2015133983A (ja) 2015-07-27
BRPI0915928B8 (pt) 2021-05-25
US9382326B2 (en) 2016-07-05
UY31987A (es) 2010-02-26
KR20130098432A (ko) 2013-09-04
SI2315780T1 (sl) 2015-11-30
US9340620B2 (en) 2016-05-17
US20100021452A1 (en) 2010-01-28
CA2730063A1 (en) 2010-01-21
JP5767109B2 (ja) 2015-08-19
BRPI0915928B1 (pt) 2020-10-20
GEP20146129B (en) 2014-08-11
EP2315780B1 (en) 2015-08-19
KR20110020914A (ko) 2011-03-03
HRP20151227T1 (hr) 2015-12-18
TWI508742B (zh) 2015-11-21
TW201006493A (en) 2010-02-16
CA2730063C (en) 2017-04-18
EA201100191A1 (ru) 2011-08-30
JO3149B1 (ar) 2017-09-20
MX2011000616A (es) 2011-02-24
IL210485A0 (en) 2011-03-31
AU2009272771A1 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
DOP2011000016A (es) Composiciones y metodos de uso para anticuerpos terapeuticos
CL2018000353A1 (es) Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
CL2008001632A1 (es) Compuestos derivados de acidos benzoilamino-indan-2-carboxilicos sustituidos, inhibidores del receptor cxcr5; composicion farmaceutica; y su uso en el tratamiento de efecciones fisiologicas inflamatorias, tales como artritis reumatoidea y asma.
GT201500294A (es) Compuestos de biaril-amida como inhibidores de cinasa
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
CL2010001637A1 (es) Compuestos derivados de isoindolonas; composición farmacéutica que los comprende; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas y/o inflamatorias tales como cáncer, artritis reumatoidea entre otras.
ECSP11010932A (es) Compuestos de azaindazol como antagonistas del receptor de ccr1
UY32966A (es) Octahidropirrolo (3,4-c) pirroles disustituidos como moduladores del receptor de orexina
CL2008001335A1 (es) Compuestos derivados de pirrolopirimidin-7-ona, antagonistas de los receptores de purina p2x; porceso de preparacion de estos; composicion farmaceutica que los comprende; proceso de preparacion de compuestos intermediarios y usos en el tratamientos del dolor, vejiga hiperactiva, entre otras.
CL2010001641A1 (es) Compuestos derivados de heterociclos biciclicos sustituidos; composicion farmaceutica; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas e inflamatorias tales como cancer y artritis reumatoide entre otras.
EA201590590A1 (ru) Модуляторы рецептора андрогенов и их применение
EA201300730A1 (ru) Производные индазолилтриазола
UY30917A1 (es) Moduladores 2-aminopiridina del receptor histamina h
CL2015002202A1 (es) Benzamidas sustituidas con actividad hacia receptores ep4.
CL2013000714A1 (es) Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso de preparacion; composicion farmaceutica que los comprende; metodo de tratamiento; y uso del compuesto para tratar enfermedades tales como diabetes tipo 2, sindrome metabolico, dislipidemia, hipertension y esquizofrenia, entre otras.
UY32937A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
PE20170192A1 (es) Mutagenesis dirigida al sitio de anticuerpos receptor desencadenante expresado en las meloid tipo 1 (trem-1) para reducir la viscosidad
ECSP088807A (es) Tetrahidro-pirimidoazepinas como moduladores del potencial transitorio de receptor vaillinoide 1 (trpv1)
PE20170703A1 (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y metodos de uso de los mismos
UY31340A1 (es) Moduladores tieno- y furo-pirimidina del receptor de histamina h4
EA201101572A1 (ru) Композиции и способы применения терапевтических антител, специфичных в отношении субъединицы бета1 рецептора il-12
GT200800052A (es) Compuestos triciclicos utiles como agonistas de recepciones de oxitocina
UY33651A (es) Anticuerpos anti-il12rbeta1 y su uso para tratar los trastornos autoinmunes e inflamatorios
CO6341571A2 (es) Composiciones y metodos de uso para anticuerpos terapeuticos